• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by PepGen Inc.

    8/12/24 4:52:00 PM ET
    $PEPG
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PEPG alert in real time by email
    SC 13G 1 d11435208_13g.htm

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No.)*

     

     

     

    PepGen Inc.
    (Name of Issuer)

     

     

     

    Common Stock, par value $0.0001 per share
    (Title of Class of Securities)

     

     

     

    713317105
    (CUSIP Number)

     

     

     

    July 31, 2024
    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    [_] Rule 13d-1(b)

     

    [X] Rule 13d-1(c)

     

    [_] Rule 13d-1(d)

     

    __________

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     
     
    CUSIP No. 713317105    

     

    1. NAME OF REPORTING PERSONS  
      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)  
         
      Suvretta Capital Management, LLC  
         
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
        (a)  [_]
        (b)  [_]
         
    3. SEC USE ONLY  
         
         
         
    4. CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      Delaware  
         
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
         
    5. SOLE VOTING POWER  
         
      0  
         
    6. SHARED VOTING POWER  
         
      1,660,932  
         
    7. SOLE DISPOSITIVE POWER  
         
      0  
         
    8. SHARED DISPOSITIVE POWER  
         
      1,660,932  
         
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
         
      1,660,932  
         
    10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) [_]
         
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
         
      5.1%  
         
    12. TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)  
         
      IA, OO  
     
     

     

    CUSIP No. 713317105  

     

    1. NAME OF REPORTING PERSONS  
      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)  
         
      Averill Master Fund, Ltd.  
         
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
         
        (a)  [_]
        (b)  [_]
         
    3. SEC USE ONLY  
         
         
         
    4. CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      Cayman Islands  
         
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
         
    5. SOLE VOTING POWER  
         
      0  
         
    6. SHARED VOTING POWER  
         
      1,660,932  
         
    7. SOLE DISPOSITIVE POWER  
         
      0  
         
    8. SHARED DISPOSITIVE POWER  
         
      1,660,932  
         
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
         
      1,660,932  
         
    10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) [_]
         
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
         
      5.1%  
         
    12. TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)  
         
      CO  
         

     

     
     

     

    CUSIP No. 713317105    

     

    1. NAME OF REPORTING PERSONS  
      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)  
         
      Aaron Cowen  
         
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
        (a)  [_]
        (b)  [_]
         
    3. SEC USE ONLY  
         
         
         
    4. CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      U.S.A.  
         
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
         
    5. SOLE VOTING POWER  
         
      0  
         
    6. SHARED VOTING POWER  
         
      1,660,932  
         
    7. SOLE DISPOSITIVE POWER  
         
      0  
         
    8. SHARED DISPOSITIVE POWER  
         
      1,660,932  
         
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
         
      1,660,932  
         
    10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) [_]
         
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
         
      5.1%  
         
    12. TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)  
         
      IN, HC  

     

     
     

     

     

    CUSIP No. 713317105  

     

       
    Item 1. (a). Name of Issuer:
         
        PepGen Inc.
         
      (b). Address of Issuer's Principal Executive Offices:
         
       

    321 Harrison Ave. 8th Floor

    Boston, Massachusetts 02118

     

    Item 2.    
      (a) – (c) Name, Principal Business Address, and Citizenship of Persons Filing:
         
       

    Suvretta Capital Management, LLC – Delaware

    Averill Master Fund, Ltd. – Cayman Islands

        Aaron Cowen – U.S.A.
         
       

    Suvretta Capital Management, LLC:

    540 Madison Avenue, 7th Floor

    New York, New York 10022

       

    United States of America

     

    Averill Master Fund, Ltd.:

    c/o Maples Corporate Services Limited

    P.O. Box 309

    Ugland House

    Grand Cayman KY1-1104

    Cayman Islands

     

    Aaron Cowen:

    c/o Suvretta Capital Management, LLC

    540 Madison Avenue, 7th Floor

    New York, New York 10022

         
      (d).   Title of Class of Securities:
         
        Common Stock, par value $0.0001 per share (the “Common Stock”)
         
      (e). CUSIP Number:
         
        713317105
         

     

    Item 3.   If This Statement is filed pursuant to ss.240.13d-1(b) or 240.13d-2(b), or (c), check whether the person filing is a
         

     

      (a) [_] Broker or dealer registered under Section 15 of the Exchange Act (15 U.S.C. 78c).
           
      (b) [_] Bank as defined in Section 3(a)(6) of the Exchange Act (15 U.S.C. 78c).
           
      (c) [_] Insurance company as defined in Section 3(a)(19) of the Exchange Act (15 U.S.C. 78c).
           
      (d) [_] Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
           
      (e) [_] An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
           
      (f) [_] An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
           
      (g) [_] A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);
           
      (h) [_] A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C.1813);
           
      (i) [_] A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
           
      (j)   [_] Group, in accordance with s.240.13d-1(b)(1)(ii)(J).

     

     
     

     

    Item 4. Ownership.
     
    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

      (a)   Amount beneficially owned:
         
        Suvretta Capital Management, LLC – 1,660,932
        Averill Master Fund, Ltd. – 1,660,932
        Aaron Cowen – 1,660,932
         
      (b)   Percent of class:
         
        Suvretta Capital Management, LLC – 5.1%
        Averill Master Fund, Ltd. – 5.1%
        Aaron Cowen – 5.1%

     

       
      (c)   Number of shares as to which the person has:
         
        (i) Sole power to vote or to direct the vote  
             
          Suvretta Capital Management, LLC – 0
          Averill Master Fund, Ltd. – 0
          Aaron Cowen – 0
             
        (ii)   Shared power to vote or to direct the vote  
             
          Suvretta Capital Management, LLC – 1,660,932
          Averill Master Fund, Ltd. – 1,660,932
          Aaron Cowen – 1,660,932
             
        (iii) Sole power to dispose or to direct the disposition of  
             
          Suvretta Capital Management, LLC – 0
          Averill Master Fund, Ltd. – 0
          Aaron Cowen – 0
             
        (iv)   Shared power to dispose or to direct the disposition of  
             
          Suvretta Capital Management, LLC – 1,660,932
          Averill Master Fund, Ltd. – 1,660,932
          Aaron Cowen – 1,660,932

     

     

    Item 5. Ownership of Five Percent or Less of a Class.
     
    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [_].
     
      N/A
       

     
     

     

     

    Item 6. Ownership of More Than Five Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than five percent of the class, such person should be identified.  A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.
     
      N/A  
       
       
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.
     
    If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(1)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary.  If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.
     
      See Exhibit B attached hereto.
       
       
    Item 8. Identification and Classification of Members of the Group.
     
    If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group.  If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group.
     
      N/A
       
       
    Item 9. Notice of Dissolution of Group.
     
    Notice of dissolution of a group may be furnished as an exhibit stating the date of the dissolution and that all further filings with respect to transactions in the security reported on will be filed, if required, by members of the group, in their individual capacity.  See Item 5.
     
      N/A
       
       
    Item 10. Certification.
     
      (b) The following certification shall be included if the statement is filed pursuant to §240.13d-1(c):
         
        By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     

     
     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

      August 12, 2024
      (Date)
       
      Suvretta Capital Management, LLC*
       
      By:  /s/ Aaron Cowen
      (Signature)
       
      Authorized Signatory
     

    (Name/Title)

     

    Averill Master Fund, Ltd.*

       
      By:  /s/ Aaron Cowen
      (Signature)
       
      Director
      (Name/Title)
     

     

    Aaron Cowen*

     

      /s/ Aaron Cowen
      (Signature)
       
       

    *Each Reporting Person disclaims beneficial ownership over the securities reported herein except to the extent of its pecuniary interest therein.

     

    The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative other than an executive officer or general partner of the filing person, evidence of the representative's authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.

    Note. Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See s.240.13d-7 for other parties for whom copies are to be sent.

    Attention. Intentional misstatements or omissions of fact constitute Federal criminal violations (see 18 U.S.C. 1001).

     

     

     
     

     

    Exhibit A

     

    AGREEMENT

     

    The undersigned agree that this Schedule 13G dated August 12, 2024 relating to the Common Stock of PepGen Inc. shall be filed on behalf of the undersigned.

      August 12, 2024
      (Date)
       
      Suvretta Capital Management, LLC
       
      By:  /s/ Aaron Cowen
      (Signature)
       
      Authorized Signatory
     

    (Name/Title)

     

    Averill Master Fund, Ltd.

       
      By:  /s/ Aaron Cowen
      (Signature)
       
      Director
      (Name/Title)
     

     

    Aaron Cowen

     

      /s/ Aaron Cowen
      (Signature)
       
       

     

     
     

     

    Exhibit B

     

    Aaron Cowen has beneficial ownership by virtue of his role as a control person of Suvretta Capital Management, LLC.

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Get the next $PEPG alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PEPG

    DatePrice TargetRatingAnalyst
    12/16/2024$3.00Neutral → Underperform
    BofA Securities
    7/31/2024$12.00Buy → Neutral
    BofA Securities
    12/21/2022$26.00Buy
    H.C. Wainwright
    More analyst ratings

    $PEPG
    Leadership Updates

    Live Leadership Updates

    See more
    • PepGen Appoints Kasra Kasraian, PhD, as Chief Technology Officer

      PepGen Inc. (NASDAQ:PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced the appointment of Kasra Kasraian, PhD, as Chief Technology Officer (CTO). Dr. Kasraian brings over 25 years of experience in product and process development, CMC strategy, and technical operations, spanning small and large molecules, as well as cell and gene therapies. "We are pleased to welcome Kasra to our executive leadership team," said James McArthur, PhD, President and Chief Executive Officer of PepGen. "He brings a rare depth of expertise in product

      5/20/25 7:00:00 AM ET
      $PEPG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PepGen Announces Appointment of Two New Directors to its Board

      PepGen Inc. (NASDAQ:PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced the appointments of Lisa Wyman and Mitchell H. Finer, PhD, to its Board of Directors. Ms. Wyman and Dr. Finer are industry veterans, each bringing decades of executive experience in the life sciences to the Company. "We are thrilled to welcome Lisa and Mitch to our Board of Directors," said James McArthur, PhD, President and CEO of PepGen. "Lisa's proven ability to scale manufacturing for mid- to late-stage clinical trials and guide clinical-stage companies

      3/31/25 4:05:00 PM ET
      $PEPG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PepGen Appoints Paul Streck, M.D., MBA, as Executive Vice President, Head of Research & Development

      PepGen Inc. (NASDAQ:PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced the appointment of Paul Streck, M.D., MBA, as Executive Vice President, Head of Research & Development (R&D), effective immediately. Dr. Streck will join the PepGen Executive Team and will be responsible for leading the R&D organization. "We are very pleased that Paul is joining PepGen at such an important time for the Company," said James McArthur, Ph.D., President and CEO of PepGen. "Throughout his career, Paul has served in leadership roles across both l

      8/20/24 8:00:00 AM ET
      $PEPG
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PEPG
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Technical Officer Kasraian Kasra was granted 16,750 shares (SEC Form 4)

      4 - PepGen Inc. (0001835597) (Issuer)

      5/21/25 4:47:34 PM ET
      $PEPG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3 filed by new insider Kasraian Kasra

      3 - PepGen Inc. (0001835597) (Issuer)

      5/21/25 4:00:51 PM ET
      $PEPG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President and CEO Mcarthur James G bought $13,550 worth of shares (10,000 units at $1.35), increasing direct ownership by 10% to 113,913 units (SEC Form 4)

      4 - PepGen Inc. (0001835597) (Issuer)

      4/22/25 7:01:12 AM ET
      $PEPG
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PEPG
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by PepGen Inc.

      SC 13G/A - PepGen Inc. (0001835597) (Subject)

      11/14/24 4:31:29 PM ET
      $PEPG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by PepGen Inc.

      SC 13G - PepGen Inc. (0001835597) (Subject)

      11/14/24 11:10:10 AM ET
      $PEPG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by PepGen Inc.

      SC 13G/A - PepGen Inc. (0001835597) (Subject)

      11/12/24 8:57:04 AM ET
      $PEPG
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PEPG
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • PepGen downgraded by BofA Securities with a new price target

      BofA Securities downgraded PepGen from Neutral to Underperform and set a new price target of $3.00

      12/16/24 12:07:01 PM ET
      $PEPG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PepGen downgraded by BofA Securities with a new price target

      BofA Securities downgraded PepGen from Buy to Neutral and set a new price target of $12.00

      7/31/24 11:28:59 AM ET
      $PEPG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • H.C. Wainwright initiated coverage on PepGen with a new price target

      H.C. Wainwright initiated coverage of PepGen with a rating of Buy and set a new price target of $26.00

      12/21/22 9:28:36 AM ET
      $PEPG
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PEPG
    Financials

    Live finance-specific insights

    See more
    • PepGen Announces Positive Initial Results, Including Robust Splicing Correction, from Ongoing FREEDOM-DM1 Trial in Patients with DM1

      – Significant mean splicing correction of 29.1% following a single dose of PGN-EDODM1 at 10 mg/kg – – PGN-EDODM1 observed to have favorable emerging safety profile – – Conference call scheduled today at 8:00 a.m. ET – PepGen Inc. (NASDAQ:PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced initial positive clinical data from the 5 and 10 mg/kg dose cohorts in the ongoing FREEDOM-DM1 Phase 1 trial investigating PGN-EDODM1 in myotonic dystrophy type 1 (DM1). "These results far exceeded our expectations for splicing correctio

      2/24/25 7:00:00 AM ET
      $PEPG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PepGen Announces Positive Data from Low-Dose Cohort of PGN-EDO51 in Ongoing CONNECT1-EDO51 Phase 2 Clinical Trial for Treatment of Duchenne Muscular Dystrophy

      – PGN-EDO51 at 5 mg/kg was well tolerated, and all patients continued to long-term extension portion of trial. Dosing of second cohort at 10 mg/kg is ongoing – – Four doses of PGN-EDO51 at 5 mg/kg achieved mean exon skipping levels of 2.15% after three months of dosing – – PGN-EDO51 at 5 mg/kg showed mean muscle-adjusted dystrophin level of 1.49%, a 0.70% increase from baseline, after three months of dosing – – PGN-EDO51 at 5 mg/kg showed mean absolute dystrophin level of 0.61%, a 0.26% increase from baseline, after three months of dosing – – Conference call scheduled for 4:30 p.m. ET – PepGen Inc. (NASDAQ:PEPG), a clinical-stage biotechnology company advancing the next generation

      7/30/24 4:02:00 PM ET
      $PEPG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PepGen to Host Fourth Quarter and Full Year 2022 Financial Results Call

      BOSTON, March 16, 2023 (GLOBE NEWSWIRE) -- PepGen Inc. (NASDAQ:PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, will report its fourth quarter and full year 2022 financial results and provide a corporate update on Thursday, March 23, 2023. PepGen's management will host a conference call and live audio webcast to discuss these results and provide a corporate update at 4:30pm ET. The event will be webcast live under the Events & Presentations section of the Investor Relations section of PepGen's website. A replay of the event will be archived

      3/16/23 8:00:00 AM ET
      $PEPG
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PEPG
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • PepGen Appoints Kasra Kasraian, PhD, as Chief Technology Officer

      PepGen Inc. (NASDAQ:PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced the appointment of Kasra Kasraian, PhD, as Chief Technology Officer (CTO). Dr. Kasraian brings over 25 years of experience in product and process development, CMC strategy, and technical operations, spanning small and large molecules, as well as cell and gene therapies. "We are pleased to welcome Kasra to our executive leadership team," said James McArthur, PhD, President and Chief Executive Officer of PepGen. "He brings a rare depth of expertise in product

      5/20/25 7:00:00 AM ET
      $PEPG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PepGen Reports First Quarter 2025 Financial Results and Recent Corporate Highlights

      – Reported positive DM1 patient data with mean splicing correction of 29.1% following a single dose of PGN-EDODM1 at 10 mg/kg – – FREEDOM-DM1 data from 15 mg/kg cohort expected in the second half of 2025 – – CONNECT1-EDO51 data from 10 mg/kg cohort expected in the third quarter of 2025 – PepGen Inc. (NASDAQ:PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today reported financial results and recent corporate highlights for the quarter ended March 31, 2025. "Our EDO platform's unique ability to efficiently deliver oligonucleotides into the

      5/8/25 8:00:00 AM ET
      $PEPG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PepGen to Present at the 24th Annual Needham Virtual Healthcare Conference

      PepGen Inc. (NASDAQ:PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that James McArthur, PhD, President and CEO of PepGen, will present at the 24th Annual Needham Virtual Healthcare Conference on Wednesday, April 9, 2025 at 1:30pm ET. A webcast of the corporate presentation will be available on the "Events & Presentations" page within the Investors section of the PepGen website at https://investors.pepgen.com/. A replay of the webcast will be available on the PepGen website for 90 days following the presentation date. About

      4/2/25 4:05:00 PM ET
      $PEPG
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PEPG
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • President and CEO Mcarthur James G bought $13,550 worth of shares (10,000 units at $1.35), increasing direct ownership by 10% to 113,913 units (SEC Form 4)

      4 - PepGen Inc. (0001835597) (Issuer)

      4/22/25 7:01:12 AM ET
      $PEPG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President and CEO Mcarthur James G bought $47,725 worth of shares (41,500 units at $1.15), increasing direct ownership by 66% to 103,913 units (SEC Form 4)

      4 - PepGen Inc. (0001835597) (Issuer)

      4/9/25 7:40:15 AM ET
      $PEPG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Oxford Science Enterprises Plc bought $10,559,640 worth of shares (879,970 units at $12.00), increasing direct ownership by 23% to 4,755,388 units (SEC Form 4) (Amendment)

      4/A - PepGen Inc. (0001835597) (Issuer)

      4/9/24 5:24:38 PM ET
      $PEPG
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PEPG
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by PepGen Inc.

      SCHEDULE 13G/A - PepGen Inc. (0001835597) (Subject)

      5/15/25 4:32:37 PM ET
      $PEPG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by PepGen Inc.

      SCHEDULE 13G/A - PepGen Inc. (0001835597) (Subject)

      5/15/25 8:22:12 AM ET
      $PEPG
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PepGen Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - PepGen Inc. (0001835597) (Filer)

      5/8/25 8:05:08 AM ET
      $PEPG
      Biotechnology: Pharmaceutical Preparations
      Health Care